Mauna Kea Technologies Announces the Opening of the First Italian Center of Excellence for the Use of Cellvizio to Identify and Treat Food Intolerance in Adults - Seite 2

“Many patients live with undiagnosed food intolerances, simply because existing testing methods cannot identify the underlying issues. The Cellvizio Food Intolerance procedure is a simple, visual and clinically proven way to determine whether the patient has a previously undetected food intolerance. I couldn’t be more excited to be the first in Italy to perform this procedure and to establish the first Center of Excellence in our country”, said Dr. Alberto Larghi, Gastroenterology and Digestive Endoscopy Specialist. “My vision is that by adopting novel technologies like Cellvizio, we can collectively improve the lives of the patients we serve.”

Next financial release:
Financial results Full Year 2023 and Trading Update Q1 2024, on April 25, 2024 after market close.

***

About IBS & Food Intolerance
Irritable bowel syndrome affects approximately 10-15% of the European population, although prevalence rates vary depending on the classification used and the country surveyed. Moreover, up to 70% of individuals with irritable bowel syndrome may not have been formally diagnosed, a condition reportedly linked to atypical food intolerance in the majority of cases, characterized by a group of symptoms including abdominal pain, bloating, and changes in bowel habits (diarrhea, constipation, or both). This condition significantly affects the quality of life of those affected who often face a protracted and distressing journey of medical consultation that could last 2 to 3 years on average with no guaranteed path to identifying the underlying cause of their symptoms.

About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit www.maunakeatech.com.